ADT and ARSI inhibit androgen driven PCa (de Brot et al., 2015), but the emergence of castrate-resistant PCa (CRPC) where the AR continues to orchestrate pro-oncogenic signaling occurs frequently in ADT-treated patients (Sharma et al., 2013). The gene discussed is AR; the disease is posterior cortical atrophy.